Get the Stockscreener App
5.44
3.37%
-0.19
Pre-market:
4.96
-0.48
-8.82%
Alpha Cognition Inc stock is traded at $5.44, with a volume of 6,361.
It is down -3.37% in the last 24 hours and down -9.78% over the past month.
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
See More
Previous Close:
$5.63
Open:
$5.54
24h Volume:
6,361
Relative Volume:
0.07
Market Cap:
$87.15M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-1.9223
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
+2.45%
1M Performance:
-9.78%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.4279
$5.79
1-Week Range:
$5.23
$5.79
52-Week Range:
$4.66
$7.00
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
5.44 | 87.15M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.77 | 129.62B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
666.87 | 72.91B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
604.96 | 36.76B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.76 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.19 | 27.86B | 3.32B | -860.46M | -1.04B | -8.32 |
Alpha Cognition Inc Stock (ACOG) Latest News
Acetylcholinesterase Inhibitors Market is expected to reach - openPR
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition sets new executive and director compensation By Investing.com - Investing.com Australia
Alpha Cognition sets new executive and director compensation - Investing.com India
Alpha Cognition Inc. (NASDAQ:ACOG) surges 13%; retail investors who own 46% shares profited along with institutions - Yahoo Finance
Institutions profited after Alpha Cognition Inc.'s (NASDAQ:ACOG) market cap rose US$12m last week but retail investors profited the most - Simply Wall St
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease - Business Wire
Acetylcholinesterase Inhibitors Market Size, Share, Industry - openPR
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Newsfile
Stonegate Capital Partners Initiates Coverage on Alpha Cognition's Innovative Alzheimer's Therapy ZUNVEYL - citybuzz -
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - The Manila Times
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - GlobeNewswire Inc.
Alpha Cognition to delist from Canadian Securities Exchange - MSN
Acetylcholinesterase Inhibitors Market: Industry Growth - openPR
Moves at FDA, NIH - BioCentury
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - BioSpace
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon - Verywell Health
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch - TipRanks
Alpha Cognition Expands Leadership Team Ahead of Landmark Alzheimer's Drug Launch in 2025 - StockTitan
Top Dividend Stocks For Reliable Income In January 2025 - Simply Wall St
Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - JCN Newswire
Alpha Cognition licenses ZUNVEYL in Asia and Oceania By Investing.com - Investing.com Canada
ACOG News Today | Why did Alpha Cognition stock go up today? - MarketBeat
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - AOL
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - The Manila Times
Alpha Cognition licenses ZUNVEYL in Asia and Oceania - Investing.com India
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL - TipRanks
Alpha Cognition Lands $44M ZUNVEYL Licensing Deal for Massive Asian Alzheimer's Market - StockTitan
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - Business Wire
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - BioSpace
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Alpha Cognition files to sell 1.45M common shares for holders - MSN
Alpha Cognition announces private sale of equity securities - Investing.com
Alpha Cognition stock hits 52-week low at $5.3 amid market challenges - Investing.com Australia
Alpha Cognition Raises $52.8 Million in Stock Offering - TipRanks
Alpha Cognition Raises $52.8M in Nasdaq IPO, Strengthens Alzheimer's Drug Commercialization Plans - StockTitan
Alpha Cognition Reports Promising Data for Brain Injury Drug - TipRanks
CSE Bulletin: DelistAlpha Cognition Inc. (ACOG) - Newsfile
Alpha Cognition Announces Voluntary Delisting from CSE - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment - MSN
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment | 2024-12-11 | Investing News - Stockhouse Publishing
Alpha Cognition Announces Positive Interim Pre-Clinical Data for Alpha-1062 Use in A Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Marketscreener.com
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - BioSpace
About Us - Financial Content
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Inc. announced that it expects to receive $46.149996 million in funding - Marketscreener.com
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com India
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - Business Wire
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alpha Cognition Inc Stock (ACOG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):